A selection of major announcements

1. China Mobile's 5G package users increased by a net increase of 2002 million in November

$CHINA MOBILE (00941.HK)$Operating data for November was released, and the number of 5G package customers increased by a net increase of 2.024 million during the month. By the end of November 2023, the number of 5G package customers had reached 778.8 million. Data show that in November 2023, the total number of mobile users in China reached 9990,94.8 million, with a net increase of 171,000 customers in that month.

2. China Telecom's 5G package subscribers increased by a net increase of 3.31 million in November

$CHINA TELECOM (00728.HK)$Operating data for November was released. The number of mobile users increased by 590,000 in that month, bringing the total number of mobile users to 407.23 million. Among them, there was a net increase of 3.31 million 5G package users, and the total number of 5G package users was 314.63 million.

3. China Tobacco Hong Kong expects annual net profit growth of not less than 50%

$CTIHK (06055.HK)$According to the announcement of Profit, it is estimated that the annual net profit increase will not be less than 50%. The Brazilian business grew mainly due to the increase in overall unit sales prices and the resumption of consumption in duty-free shops.

4. Prudential and CITIC Finance plan to increase capital in CITIC Prudential Life

$PRU (02378.HK)$It was announced that the joint venture “CITIC Prudential Life” with CITIC Finance will each invest 1.25 billion yuan to increase the capital of the joint venture “CITIC Prudential Life”. After the capital increase is completed, the registered capital of CITIC Prudential Life will increase from 2.36 billion yuan to 4.86 billion yuan. Both parties will keep half of their shares unchanged, but they are still awaiting approval from the regulatory authorities. After the capital increase is completed, CITIC Prudential Life's core and comprehensive solvency ratios are expected to be 121% and 215% respectively, which is far higher than regulatory requirements.

Pharmaceutical Innovation

$ZYLOXTB-B (02190.HK)$: The ZENFLEX peripheral vascular stent system completed post-marketing clinical trials in the European Union and enrolled all patients

$OCUMENSION-B (01477.HK)$: OT-703 approved for listing in Hong Kong

$CANSINOBIO (06185.HK)$: Adsorbed tetanus vaccine commences phase I clinical trials and completes enrollment of the first subject

$HANSOH PHARMA (03692.HK)$HS-20093 license agreement with GSK, milestone payments of up to $1,525 million

Important matters

$PRADA (01913.HK)$Proposed acquisition of US properties for US$425 million

$HUABAO INTL (00336.HK)$: Group member companies have further subscribed to financial products, totaling 480 million yuan

Repurchase cancellation

$TENCENT (00700.HK)$On December 20, 1.28 million shares were repurchased at a cost of HK$403 million

$AIA (01299.HK)$On December 20, it spent HK$134 million to repurchase 199,000 shares

$LI NING (02331.HK)$On December 20, 5,537 million shares were repurchased at a cost of HK$107 million

$WUXI BIO (02269.HK)$On December 20, 1.34 million shares were repurchased at a cost of HK$386.08 million

$SWIRE PACIFIC A (00019.HK)$On December 20, 304,500 shares were repurchased at a cost of HK$18.952 million

$COSCO SHIP HOLD (01919.HK)$On December 20, 2.49 million shares were repurchased at a cost of HK$18.932,800

$CHINA LONGYUAN (00916.HK)$On December 20, 451,000 shares were repurchased at a cost of HK$2.63 million

$SKYWORTH GROUP (00751.HK)$On December 20, 900,000 shares were repurchased at a cost of HK$2,627 million

Editor/Corrine